已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial

医学 利福平 肺结核 人口 不利影响 儿科 随机对照试验 意向治疗分析 内科学 外科 环境卫生 病理
作者
Rovina Ruslami,Federica Fregonese,Lika Apriani,Leila Barss,Nancy Bedingfield,Victor Chiang,Victoria Cook,Dina Fisher,Eri Flores,Greg J. Fox,James C. Johnston,Rachel Lim,Richard Long,Catherine Paulsen,Thu Anh Nguyen,Nguyen Viet Nhung,Diana Gibson,Chantal Valiquette,Andrea Benedetti,Dick Menzies
出处
期刊:The Lancet Respiratory Medicine [Elsevier]
卷期号:12 (6): 433-443 被引量:2
标识
DOI:10.1016/s2213-2600(24)00076-6
摘要

Background Tuberculosis preventive treatment (TPT) is a key component of tuberculosis elimination. To improve completion and reduce the burden for people and health systems, short, safe, and effective TPT regimens are needed. We aimed to compare safety and treatment completion of various doses and durations of rifampicin in people who were recommended to receive TPT. Methods This partially blinded, parallel-arm, non-inferiority, randomised, controlled, phase 2b trial was done at seven university-affiliated clinics in Canada, Indonesia, and Viet Nam. Participants aged 10 years or older were included if they had an indication for TPT according to WHO guidelines for Indonesia and Viet Nam, or Canadian guidelines for Canadian sites, and a positive tuberculin skin test or interferon-γ release assay. Participants were randomly assigned (1:1:1) to receive oral rifampicin at 10 mg/kg once daily for 4 months (standard-dose group), 20 mg/kg daily for 2 months (20 mg/kg group), or 30 mg/kg daily for 2 months (30 mg/kg group). The randomisation sequence was computer generated with blocks of variable size (three, six, and nine) and stratified by country for Indonesia and Viet Nam, and by city within Canada. Participants and investigators were masked to dose in high-dose groups, but unmasked to duration in all groups. The two co-primary outcomes were safety (in the safety population, in which participants received at least one dose of the study drug) and treatment completion (in the modified intention-to-treat [mITT] population, excluding those ineligible after randomisation). Protocol-defined adverse events were defined as grade 3 or worse, or rash or allergy of any grade, judged by an independent and masked panel as possibly or probably related to the study. A margin of 4% was used to assess non-inferiority. This study is registered with ClinicalTrials.gov, NCT03988933 (active). Results Between Sept 1, 2019, and Sept 30, 2022, 1692 people were assessed for eligibility, 1376 were randomly assigned, and eight were excluded after randomisation. 1368 participants were included in the mITT population (454 in the standard group, 461 in the 20 mg/kg group, and 453 in the 30 mg/kg group). 589 (43%) participants were male and 779 (57%) were female. 372 (82%) in the standard-dose group, 329 (71%) in the 20 mg/kg group, and 293 (65%) in the 30 mg/kg group completed treatment. No participants in the standard-dose group, one (<1%) of 441 participants in the 20 mg/kg group, and four (1%) of 423 in the 30 mg/kg group developed grade 3 hepatotoxicity. Risk of protocol-defined adverse events was higher in the 30 mg/kg group than in the standard-dose group (adjusted risk difference 4·6% [95% CI 1·8 to 7·4]) or the 20 mg/kg group (5·1% [2·3 to 7·8]). There was no difference in the risk of adverse events between the 20 mg/kg and standard-dose groups (–0·5% [95% CI –2·4 to 1·5]; non-inferiority met). Completion was lower in the 20 mg/kg group (–7·8% [95% CI –13·6 to –2·0]) and the 30 mg/kg group (–15·4% [–21·4 to –9·4]) than in the standard-dose group. Interpretation In this trial, 2 months of 30 mg/kg daily rifampicin had significantly worse safety and completion than 4 months of 10 mg/kg daily and 2 months of 20 mg/kg daily (the latter, a fully blinded comparison); we do not consider 30 mg/kg to be a good option for TPT. Rifampicin at 20 mg/kg daily for 2 months was as safe as standard treatment, but with lower completion. This difference remains unexplained. Funding Canadian Institutes of Health Research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
阿牛奶发布了新的文献求助10
3秒前
银杏叶完成签到 ,获得积分10
4秒前
后陡门爱神完成签到 ,获得积分10
4秒前
LynSharonRose完成签到,获得积分10
5秒前
2220完成签到 ,获得积分10
6秒前
shc发布了新的文献求助10
6秒前
小酒很努力吖完成签到 ,获得积分10
10秒前
天真之桃发布了新的文献求助10
11秒前
Akim应助阿牛奶采纳,获得10
11秒前
燊yy发布了新的文献求助30
11秒前
13秒前
Odile完成签到 ,获得积分10
14秒前
guard发布了新的文献求助30
18秒前
天真之桃完成签到,获得积分10
23秒前
帅气的沧海完成签到 ,获得积分10
23秒前
胡图图完成签到,获得积分20
26秒前
29秒前
在水一方应助胡图图采纳,获得10
30秒前
30秒前
superfatcat完成签到,获得积分10
33秒前
34秒前
杰仔发布了新的文献求助10
36秒前
Fn完成签到 ,获得积分10
39秒前
40秒前
42秒前
耶斯完成签到,获得积分10
43秒前
清风浮云完成签到,获得积分10
43秒前
胡图图发布了新的文献求助10
44秒前
Chenly完成签到,获得积分10
45秒前
无情的mm完成签到 ,获得积分10
46秒前
月流雨完成签到,获得积分10
47秒前
耶斯发布了新的文献求助10
47秒前
愉快若剑发布了新的文献求助10
47秒前
wenhuanwenxian完成签到 ,获得积分10
48秒前
君临天下完成签到,获得积分10
52秒前
小粒橙完成签到 ,获得积分10
56秒前
阿钉完成签到 ,获得积分10
56秒前
花草般的清香完成签到,获得积分20
57秒前
杨旭完成签到 ,获得积分10
1分钟前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 600
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3154769
求助须知:如何正确求助?哪些是违规求助? 2805639
关于积分的说明 7865397
捐赠科研通 2463783
什么是DOI,文献DOI怎么找? 1311600
科研通“疑难数据库(出版商)”最低求助积分说明 629647
版权声明 601832